Boston Scientific (NYSE:BSX) said Tuesday that the U.K.’s National Institute for Health and Care Excellence now provides guidance supporting the use of its GreenLight XPS laser therapy system used to treat prostatic enlargement in patients with benign prostatic hyperplasia.
NICE, which provides evidence-based guidance and standards to the U.K.’s National Health Service, said that adoption of the GreenLight XPS system to treat non high-risk patients with BPH can “significantly reduce costs for the NHS,” Marlborough, Mass.-based Boston Scientific said.
“The GreenLight XPS System is a well-established treatment to help men with BPH. It is suitable for almost all men, even those who may not be deemed fit for conventional surgery.
NICE, which provides evidence-based guidance and standards to the U.K.’s National Health Service, said that adoption of the GreenLight XPS system to treat non high-risk patients with BPH can “significantly reduce costs for the NHS,” Marlborough, Mass.-based Boston Scientific said.
“The GreenLight XPS System is a well-established treatment to help men with BPH. It is suitable for almost all men, even those who may not be deemed fit for conventional surgery.
